BioStem Technologies, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has a net cash position, so leverage is healthy.

BioStem Technologies, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioStem Technologies, Inc.'s profit margin has increased (344.07%) in the last year from 10.56% to 46.91%, signaling increasing performance

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioStem Technologies, Inc.'s return on equity of -76.13%, is lower than 15.00%, indicating bad performance

BioStem Technologies, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioStem Technologies, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

BioStem Technologies, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioStem Technologies, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

BioStem Technologies, Inc.'s yearly earnings has decreased 120.64% since last year from $31.88M to $-6.58M, signaling decreasing performance

BioStem Technologies, Inc. has insufficient data to evaluate this check.

ROIC -80.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioStem Technologies, Inc.'s 3-year revenue CAGR of 90.44% is positive, indicating growing revenue over the past 3 years

BioStem Technologies, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

BioStem Technologies, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioStem Technologies, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioStem Technologies, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioStem Technologies, Inc. is overvalued relative to its fair value price of -20.32 based on Earnings Fair Value model

BioStem Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioStem Technologies, Inc. has a price-to-book ratio of 2.31x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioStem Technologies, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue